ASCO 2013 - Poster: A phase II multicenter study of the investigational single agent orteronel (TAK-700) in non-metastatic castration-resistant prostate cancer (nmCRPC [M0]) and rising prostate-specific antigen (PSA)

CHICAGO, IL USA (UroToday.com) - Presented by Maha Hussain,¹ Paul Corn,² Dror Michaelson,³ Hans Hammers,⁴ Joshi Alumkal,⁵ Charles Ryan,⁶ Justine Bruce,⁷ Susan Moran,⁸ David Maclean,⁸ Shih-Yuan Lee,⁸ H Mark Lin,⁸ Yanyan Zhu,⁸ Hongliang Shi,⁸ Peter Mortimer,⁹ and Daniel George¹⁰ at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

¹University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA; ²M.D. Anderson Cancer Center, Houston, TX, USA; ³Massachusetts General Hospital Cancer Center, Boston, MA, USA; ⁴Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; ⁵Oregon Health & Science University, Portland, OR, USA; ⁶UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; ⁷University of Wisconsin Carbone Cancer Center, Madison, WI, USA; ⁸Millennium: The Takeda Oncology Company, Cambridge, MA, USA; ⁹Takeda Global Research & Development Centre (Europe) Ltd, London, UK; ¹⁰Duke University Medical Center, Durham, NC, USA and Members of the Prostate Cancer Clinical Trials Consortium, a program of the Department of Defense Prostate Cancer Research Program and the Prostate Cancer Foundation

View Full ASCO 2013 Coverage